Vascular Biogenics Ltd. - Ordinary Shares (VBLT): Price and Financial Metrics


Vascular Biogenics Ltd. - Ordinary Shares (VBLT): $2.33

0.00 (0.00%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

VBLT POWR Grades


  • VBLT scores best on the Sentiment dimension, with a Sentiment rank ahead of 81.37% of US stocks.
  • The strongest trend for VBLT is in Momentum, which has been heading down over the past 31 weeks.
  • VBLT ranks lowest in Momentum; there it ranks in the 9th percentile.

VBLT Stock Summary

  • Vascular Biogenics Ltd's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than just 9.2% of US listed stocks.
  • Of note is the ratio of Vascular Biogenics Ltd's sales and general administrative expense to its total operating expenses; only 11.05% of US stocks have a lower such ratio.
  • VBLT's price/sales ratio is 173.64; that's higher than the P/S ratio of 97.33% of US stocks.
  • Stocks with similar financial metrics, market capitalization, and price volatility to Vascular Biogenics Ltd are AYLA, AUTL, CLDX, PLRX, and COCP.
  • Visit VBLT's SEC page to see the company's official filings. To visit the company's web site, go to www.vblrx.com.

VBLT Price Target

For more insight on analysts targets of VBLT, see our VBLT price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $5.75 Average Broker Recommendation 1.33 (Strong Buy)

VBLT Stock Price Chart Interactive Chart >

Price chart for VBLT

VBLT Price/Volume Stats

Current price $2.33 52-week high $3.17
Prev. close $2.33 52-week low $1.01
Day low $2.30 Volume 118,851
Day high $2.36 Avg. volume 901,948
50-day MA $2.15 Dividend yield N/A
200-day MA $1.83 Market Cap 112.28M

Vascular Biogenics Ltd. - Ordinary Shares (VBLT) Company Bio


Vascular Biogenics Limited is a clinical-stage biopharmaceutical company focusing on the discovery, development, and commercialization of treatments for cancer and immune-inflammatory diseases. The company was founded in 2000 and is based in Or Yehuda, Israel.


VBLT Latest News Stream


Event/Time News Detail
Loading, please wait...

VBLT Latest Social Stream


Loading social stream, please wait...

View Full VBLT Social Stream

Latest VBLT News From Around the Web

Below are the latest news stories about Vascular Biogenics Ltd that investors may wish to consider to help them evaluate VBLT as an investment opportunity.

Vascular Biogenics, Ltd. Investors: Company Investigated by the Portnoy Law Firm

Investors can contact the law firm at no cost to learn more about recovering their lossesLOS ANGELES, June 17, 2021 (GLOBE NEWSWIRE) -- ​The Portnoy Law Firm advises Vascular Biogenics, Ltd. ("VBL" or the "Company") (NASDAQ: VBLT) investors that the firm has initiated an investigation into possible securities fraud, and may file a class action on behalf of investors. Investors are encouraged to contact attorney Lesley F. Portnoy, by phone 310-692-8883 or email: [email protected], to discuss

Yahoo | June 17, 2021

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vascular Biogenics Ltd. - VBLT

Pomerantz LLP is investigating claims on behalf of investors of Vascular Biogenics Ltd. ("VBL" or the "Company") (NASDAQ: VBLT). Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext. 7980.

Yahoo | June 16, 2021

VBL Therapeutics Provides Update on OVAL, a Phase 3 Registration Enabling Study of VB-111 in Ovarian Cancer

TEL AVIV, Israel, June 15, 2021 (GLOBE NEWSWIRE) -- VBL Therapeutics (Nasdaq: VBLT) today provided an update on its ongoing OVAL Phase 3 study investigating ofranergene obadenovec (VB-111), for the treatment of platinum-resistant ovarian cancer. The Company was notified by the U.S Food and Drug Administration (FDA) that clearance of new VB-111 batches for use in the U.S. is currently pending the completion of a technical review by the Chemistry, Manufacturing, and Controls (CMC) group, which is

Yahoo | June 15, 2021

VBL Therapeutics: Feeling Bullish After VB-111 Clinical Trial Amendment

wildpixel/iStock via Getty ImagesVBL Therapeutics (Vascular Biogenics Ltd. (VBLT)) continues to progress their flagship candidate, VB-111, an innovative gene therapy for solid tumors. Recently, the company announced that their Phase III OVAL pivotal trial in ovarian cancer has been amended to add progression-free survival “PFS” as an additional primary endpoint....

Biologics on Seeking Alpha | June 11, 2021

Analysts Are Bullish on These Healthcare Stocks: Coherus Biosciences (CHRS), Vascular Biogenics (VBLT)

Theres a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Coherus Biosciences (CHRS), Vascular Biogenics The post Analysts Are Bullish on These Healthcare Stocks: Coherus Biosciences (CHRS), Vascular Biogenics (VBLT) appeared first on Smarter Analyst .

Smarter Analyst | June 4, 2021

Read More 'VBLT' Stories Here

VBLT Price Returns

1-mo 4.95%
3-mo 13.11%
6-mo 20.73%
1-year 82.03%
3-year -16.79%
5-year -43.03%
YTD 23.28%
2020 57.50%
2019 23.71%
2018 -86.34%
2017 46.39%
2016 -7.79%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.8918 seconds.